Illumina, Inc. (FRA:ILU)

Market Cap	10.77B
Revenue (ttm)	4.19B
Net Income (ttm)	-1.17B
Shares Out	n/a
EPS (ttm)	-7.38
PE Ratio	n/a
Forward PE	n/a
Dividend	2.89 (4.28%)
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	180
Open	67.68
Previous Close	67.72
Day's Range	67.68 - 67.68
52-Week Range	62.29 - 146.32
Beta	n/a
RSI	42.65
Earnings Date	May 8, 2025

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Laboratory Analytical Instruments
• Founded: 1998
• Employees: 9,030
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ILU

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD